Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 15/20 | 0.65 |
| ▸ | CDK9 | P50750 | 12/20 | 0.65 |
| ▸ | AURKA | O14965 | 8/20 | 0.65 |
| ▸ | AURKB | Q96GD4 | 8/20 | 0.65 |
| ▸ | CDK4 | P11802 | 8/20 | 0.65 |
| ▸ | WEE1 | P30291 | 4/20 | 0.64 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.64 |
| ▸ | FLT3 | P36888 | 3/20 | 0.64 |
| ▸ | CDK7 | P50613 | 7/20 | 0.60 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.60 |
| ▸ | JAK2 | O60674 | 2/20 | 0.60 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.60 |
| ▸ | PAK4 | O96013 | 2/20 | 0.60 |
| ▸ | ABL1 | P00519 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 2/20 | 0.60 |
| ▸ | CSF1R | P07333 | 2/20 | 0.60 |
| ▸ | RET | P07949 | 2/20 | 0.60 |
| ▸ | IGF1R | P08069 | 2/20 | 0.60 |
| ▸ | MET | P08581 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4168288 | 0.91 | CDK2 (0.79) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL4166357 | 0.87 | CDK2 (0.84) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL4164090 | 0.87 | CDK2 (0.61) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL4168933 | 0.85 | CDK2 (0.62) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL4173619 | 0.84 | CDK2 (0.47) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL4159171 | 0.83 | CDK2 (0.77) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL4164547 | 0.81 | ACVR1 (0.53) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL4161793 | 0.81 | CDK2 (0.74) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL4165787 | 0.80 | CDK2 (0.77) | CDK2CDK9AURKAAURKBCDK4 | |
| SCHEMBL4163384 | 0.79 | CDK2 (0.71) | CDK2CDK9AURKAAURKBCDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | claimed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | claimed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | claimed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-05-28 | — | — | US | disclosed |
| EP-1756098-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005116025-A2 | 2-SUBSTITUTED-4-HETEROARYL-PYRIMIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137572-A1 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders | CDK2, CDK4, CDK20 | CDK2 1/4885CDK9 34/4885AURKA 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.